Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — In patients with metabolic-associated steatotic liver disease or metabolic-associated ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients who received glucagon-like peptide-1 receptor ...

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

The National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a workshop on September 10, 2024, they brought together diverse perspectives to examine the promising but ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).